TH 1940
Alternative Names: HSB-1940; TH-1940Latest Information Update: 14 Mar 2024
At a glance
- Originator Hillstream BioPharma
- Developer Tharimmune
- Class Antibodies; Antineoplastics
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Mar 2024 Tharimmune plans IND enabling studies for Cancer in 2025 (Tharimmune Pipeline, January 2024) (Tharimmune Pipeline, March 2024)
- 17 Jan 2024 Preclinical trials in Cancer in USA (Parenteral) (Tharimmune Pipeline, January 2024)
- 15 Feb 2023 Hillstream BioPharma plans a clinical trial for Cancer, in 2024